



Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

Healthcare Effectiveness Data and Information Set (HEDIS®) measure overview

People with schizophrenia or bipolar disorder who take antipsychotic medications are at increased risk of diabetes. The intent of the SSD measure is to improve the diabetes screening rate for this vulnerable population. Earlier identification and treatment of diabetes can improve physical health and quality of life.¹

Who is included in the SSD measure?

- Patients 18 to 64 years of age who had one acute inpatient stay or two outpatient visits with a diagnosis of schizophrenia, schizoaffective or bipolar disorder and take antipsychotic medications

What actions qualify for compliance?

- When patients complete a glucose test or HbA1c test

Exclusions

- Patients with diabetes and/or use hospice services
- Patients who had no antipsychotic medications dispensed and/or died during the measurement year

What can providers do to improve the compliance rate?

- Educate patients and caregivers about the increased risk of diabetes with antipsychotic medication, importance of screening for diabetes and symptoms of new onset diabetes
- Order a diabetes screening test annually and complete during the visit when possible (behavioral health providers with lab-order ability can order diabetes lab tests for patients who do not have regular contact with their primary care physician)
- Communicate and coordinate care between primary care physicians and behavioral health providers by requesting or communicating test results
- Reach out to enrollees who cancel appointments and assist with rescheduling as soon as possible

SSD antipsychotic medications

Description	Prescription
Miscellaneous antipsychotics	Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Haloperidol, Iloperidone, Loxapine, Lumateperone, Lurasidone, Molindone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Phenothiazine antipsychotics	Chlorpromazine, Fluphenazine, Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine
Psychotherapeutic combinations	Amitriptyline-perphenazine
Thioxanthenes	Thiothixene
Long-acting injections	Aripiprazole, Aripiprazole lauroxil, Fluphenazine decanoate, Haloperidol decanoate, Olanzapine, Paliperidone palmitate, Risperidone

The information offered in this flyer is based on HEDIS technical specifications. It is not meant to replace your clinical judgment.

Information regarding inclusion, compliance and exclusions for this measure were sourced from the HEDIS® Measurement Year 2025: Volume 2: Technical Specifications for Health Plans report.

Reference:

1. National Committee for Quality Assurance. (2025) HEDIS® Measurement Year 2025: Volume 1: Narrative.

NCQA copyright notice and disclaimer

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. Reprinted with permission by NCQA. © 2025 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The full text of this notice and disclaimer is available [here](https://assets.humana.com/is/content/humana/NCQA%20copyright%20notice%20and%20disclaimer.pdf): <https://assets.humana.com/is/content/humana/NCQA copyright notice and disclaimerpdf>